Precision medicine: the foundation of future cancer therapeutics
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Based on early evidence of fossilized bone tumors that were found in ancient Egyptian mummies, cancer is an ancient disease. 1 The term “carcinoma” to refer to cancer was first used around 400 BC by Hippocrates. 2 The understanding of cancer mechanisms began when John Bennett and Rudolf Virchow observed the abnormal accumulation of white blood cells in patients in 1845, which was one of the first cancers detected by microscopy. 3 In contrast to the long history of the disease, diagnosis and treatment of cancer at a cellular or molecular level is a relatively new strategy. Although the field of oncology has developed and expanded dramatically, a single drug has not yet been discovered that can cure all patients, even those with similar cancer types. We now know that cancer is an extremely heterogeneous disease, which explains differences not only between cancer cells from different patients, but also between cancer cells within a single patient. 4 Clearly, more effective strategies are critically needed to defeat the long-standing enemy known as cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
A New Initiative on Precision Medicine
Collins, F. S., & Varmus, H. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500523 · Cited by 5,202
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834 · cited 1×
“, capecitabine).(20) These two examples demonstrate how the identification of key mutations like the Bcr-Abl fusion or HER2 can clearly benefit a larger number of selected cancer patients.”
BackgroundInhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.04.025 · Cited by 3,495 · cited 1×
“CRISPR/Cas technology enables controlled exchange, insertion and deletion of DNA sequences unlike spontaneous mutation, and can easily generate animal models that mimic mutations status of patients.(38) Recently, a gene therapy trial to treat myeloma, melanoma, and sarcoma with CRISPR/Cas has been approved by the Nati…”
BackgroundA framework for human microbiome research
The Human Microbiome Project Consortium (2012) · Nature · doi:10.1038/nature11209 · Cited by 2,650
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870
Le Tourneau, C., Delord, J.-P., Gonçalves, A., Gavoille, C., Dubot, C., Isambert, N., Campone, M., Trédan, O., Massiani, M.-A., Mauborgne, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00188-6 · Cited by 1,137
Cited by
Breath Sensors for Health Monitoring
Güntner, A. T., Abegg, S., Königstein, K., Gerber, P. A., Schmidt-Trucksäss, A., & Pratsinis, S. E. (2019) · ACS Sensors · doi:10.1021/acssensors.8b00937 · Cited by 410
Morganti, S., Tarantino, P., Ferraro, E., D’Amico, P., Duso, B. A., & Curigliano, G. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-24100-1_2 · Cited by 246
The Future of Precision Medicine in the Cure of Alzheimer’s Disease
Arafah, A., Khatoon, S., Rasool, I., Khan, A., Rather, M. A., Abujabal, K. A., Faqih, Y. A. H., Rashid, H., Rashid, S. M., Bilal Ahmad, S., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11020335 · Cited by 133
“Numerous specialities, including cancer and cardiology, have started to devote their efforts toward a more precise means of executing medical procedures since its introduction [12,13].”
BackgroundFairness in Precision Medicine
Ferryman, K. (2018) · doi:10.69985/tbql1779 · Cited by 94
Ghoreyshi, N., Heidari, R., Farhadi, A., Chamanara, M., Farahani, N., Vahidi, M., & Behroozi, J. (2025) · Discover Oncology · doi:10.1007/s12672-025-01816-9 · Cited by 91
Metadata
- Authors
- Shin, S. H., Bode, A. M., & Dong, Z.
- Venue
- npj Precision Oncology
- Published
- 2017-04-24
- Volume
- 1
- Issue
- 1
- Pages
- 12-12
- ISSN
- 2397-768X (ISSN-L)
- OpenAlex
- W2607067837
- Cited by
- 128
- References
- 11
- FWCI
- 3.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Precision medicine: the foundation of future cancer therapeutics. https://app.cochat.ai/papers/10.1038/s41698-017-0016-z
- The paper
- Shin, S. H., Bode, A. M., & Dong, Z. (2017). Precision medicine: the foundation of future cancer therapeutics. npj Precision Oncology. https://doi.org/10.1038/s41698-017-0016-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.